MAZE — Maze Therapeutics, Inc.

—
Nasdaq · Health Care · Biotechnology · CIK 1842295 ·
Last close
$32.87
Market Cap
$1.80B
52W High
$53.65
52W Low
$21.95
ADV30
740,035
Next earnings
2026-11-09
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease. It has a license agreement with Trace Neuroscience, Inc. to discovery research program targets UNC13A; the Shionogi & Co., Ltd to research, develop, manufacture, and commercialize MZE001; and Neurocrine Biosciences, Inc. to discover research program that targets ATXN2. The company was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -51,517,000 -47,969,000 511,557,000 154,156,000 83,012,000
Jun 2026 0 — -48,035,000 -44,727,000 531,625,000 202,643,000 78,501,000
Mar 2026 20,000,000 — -26,553,000 -24,208,000 419,710,000 198,766,000 78,009,000
Dec 2025 0 — -38,059,000 -34,568,000 397,127,000 189,247,000 42,161,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-114,739,000
Investing CF
$-257,028,000
Financing CF
$209,149,000
CapEx
$-522,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.65
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-606,451,000
Inventory
—
Receivables
$20,000,000
ST Investments
$235,502,000
EBIT TTM
$-152,191,000
Pretax Income TTM
$-151,472,000
Interest Exp TTM
$2,772,000
Analysts
13

Yahoo Snapshot (yfinance, live)

Total Revenue
$20,000,000
EBITDA
$-162,444,992
Free Cash Flow
$-68,622,000
Enterprise Value
$1,547,264,256
Total Cash
$389,657,984
Total Debt
$59,643,000
Shares Out
54,683,345
Trailing EPS
$-2.62
Book Value
$7.59
ROE
-37.5%
ROA
-22.0%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -142,899,000 -131,120,000 397,127,000 42,161,000 354,966,000 -111,940,000
Dec 2024 167,500,000 57,586,000 52,231,000 240,542,000 551,725,000 -311,183,000 75,954,000
Dec 2023 0 -98,551,000 -100,415,000 71,504,000 445,352,000 -373,848,000 -86,827,000
Dec 2022 0 -111,026,000 -114,940,000 149,957,000 432,416,000 -282,459,000 -99,203,000

TTM Snapshot

Revenues TTM
$20,000,000
NetIncome TTM
$-133,590,000
OpCashFlow TTM
—
Assets (Latest)
$531,625,000
Forward EPS
$-3.30

Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)

max pain strike: $20.00 · spot: $31.20 · call volume: 19 · put volume: 1
Expected Move to 2027-01-15: ±$12.75 (40.87%) — implied range $18.45 – $43.95 · ATM straddle on $30.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
COAG Hemab Therapeutics Holdings, Inc. $1.83B $39.06 —
REPL Replimune Group, Inc. $1.87B $19.69 —
RXRX RECURSION PHARMACEUTICALS, INC. $1.69B $2.72 —
BCRX BIOCRYST PHARMACEUTICALS INC $1.93B $7.50 —
LYCA Lycia Therapeutics, Inc. $1.61B $30.92 —

News headlines (Yahoo Finance, 1h cache)

Maze Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights
2026-11-09 21:05 · Yahoo
Wall Street Analysts Predict a 93.92% Upside in Maze Therapeutics, Inc. (MAZE): Here's What You Should Know
2026-11-04 13:55 · Yahoo
Maze Therapeutics to Participate in Upcoming Investor Conferences
2026-11-03 12:00 · Yahoo
What Makes Maze Therapeutics, Inc. (MAZE) a New Buy Stock
2026-10-19 15:00 · Yahoo
How Much Upside is Left in Maze Therapeutics, Inc. (MAZE)? Wall Street Analysts Think 123.39%
2026-10-19 12:55 · Yahoo
Pompe Disease Market Set for Expansion During the Forecast Period (2026-2036) as Growth is Fueled by Next-Generation ERTs, Newborn Screening, and Pipeline Innovation | DelveInsight
2026-10-13 14:31 · Yahoo
Maze Therapeutics to Present Data from MZE829 and MZE782 Programs at ASN Kidney Week 2026
2026-10-06 20:05 · Yahoo
Could Vertex Pharmaceuticals (VRTX)’s Kidney Breakthrough Unlock a New Opportunity for Maze Therapeutics (MAZE)?
2026-09-29 00:37 · Yahoo
Maze Therapeutics (MAZE) Shares Moved, So What Is Driving Attention Now?
2026-09-25 04:23 · Yahoo
Maze Therapeutics Shares Rise 2.9% After CIBC Initiates Coverage
2026-09-23 12:48 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.